Keymed Biosciences, Inc. (HK:2162) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keymed Biosciences Inc. has entered an exclusive license agreement with Platina Medicines Ltd, granting them rights to develop, manufacture, and commercialize the bispecific antibody CM336 outside China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of $16 million to Keymed and potential milestone payments up to $610 million, along with royalties on sales. This agreement aims to expand Keymed’s global presence and maximize the commercial potential of its technology.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.